Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.42 USD
+0.15 (6.61%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.41 -0.01 (-0.41%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RGLS 2.42 +0.15(6.61%)
Will RGLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RGLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGLS
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Other News for RGLS
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
Regulus files to sell 62.5M shares of common stock for holders
Regulus files to sell 62.5M shares of common stock for holders
Buy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)